Theratechnologies Inc T.TH

Oncology event at Cedars-Sina

[scarlet1967]

 

This is a virtual event by Cedars-Sinai which is one of the CROs’ running the TH1902 program.

They will be discussing among others molecularly-targeted therapies, one of speakers is Dr. Mita discussing “Breakthrough targets and therapeutics in the pipeline”, she had also conducted contracted research for THTX. It will be interesting to know whether this discussion has anything to do with TH19 series.

 

 

10th Annual New Therapeutics in Oncology: The Road to Personalized Medicine Featuring The Fenmore Lectureship and The Redlich Lectureship

 

“This important educational activity will provide guidance to front-line and oncology clinicians, nurses, physicians, pharmacists, nurse practitioners, physician assistants and pharmacists, with the most current information available about new agents in oncology and translating of the latest research to their patients. The conference will cover drug and treatment updates with a focus on myeloma, gynecological malignancies, hematologic malignancies, sarcoma, bladder cancer and GI malignancies. The conference features a comprehensive review of new drugs approved along with their mechanism of action, next generation CAR cell therapies and a keynote lecture outlining advances in immunotherapy. Next generation studies will also be addressed, and the conference will offer participants a session designed to provide insight into the latest advances in lung cancer treatment, including integration of new molecularly-targeted therapies and immunotherapy.”

 

Friday, November 12, 2021

Breakthrough targets and therapeutics in the pipeline

2:10PM - 2:40PM

Monica M. Mita, MD 

 

Monica M. Mita, MD

Co-Director, Experimental Therapeutics Program

Cedars-Sinai

Course Director, Faculty

Contracted Research-Boehringer Ingelheim Pharmaceuticals, Inc. Tesaro Alliance Sanofi-Aventis Astex Pharmaceuticals, Inc. Pfizer Inc., U.S. Pharmaceuticals Group BeiGene Hoffman-La Roche Medivir AB Astra Zeneca, L.P. Merus Southwest Oncology Group Seagen (Seattle Genetics, Inc.) Amphivena Therapeutics Hummingbird Bioscience Immix Biopharma, Inc. Spring Bank Pharmaceuticals Changchun Intellicrown Pharmaceutical Co., Ltd Daiichi Sankyo Genzada Pharmaceuticals Incyte Corporation Kronos Bio Linnaeus Therapeutics, Inc. AbbVie Minneamrita Therapeutics, LLC Molecular Template, Inc. Oxford Bio Therapeutics Rgenix, Inc. SQZ Biotechnologies Tizona Therapeutics HiberCell, Inc Jounce Therapeutics Syros Pharmaceuticals, Inc Theratechnologies Inc. NeuPharma, Inc.

 

https://cedars.cloud-cme.com/course/courseoverview?P=5&EID=15247

[qwerty22]

By that date hopefully they have something to talk about. Great find.

[SPCEO1]

I believe we can be fairly certain the phase 1a will be completed by mid-November. But we would likely need TH to announce something about its phase 1a data first as it would most likely not be announced at such a conference.

[jfm1330]

Next Sunday 21 days will have passed since the KOL presentaion on oncology. So a full cycle of treatment and no news that the MTD is reached. In the next CC we should have confirmation that they are now above the MTD of free docetaxel. We should also be able to guauge if they still seem as confident.

[archeo753]

Finally got around to watching the presentation today.  Loved the smiles during the Q+A.  Thanks to all who asked such great questions!  Highly recommended to anyone else who hasn't watched it yet. 

[jfm1330]

As I wrote here before, they already have pharmacokinetic data from the few first patients injected with TH1902. So the know the levels of free docetaxel and TH1902 in the bloodstream over time and they can compare it to animal data. So they already have a pretty good idea of how the drug is behaving in the blood after injection. If free docetaxel is low and TH1902 is quickly decreasing, there are